Fujifilm Diosynth Biotechnologies Denmark Aps
Biotek Allé 1, 3400 Hillerød, CVR 26060702
Rank Profit for the year
Rank in industry
2/135
"Top 10%"
Rank in Denmark
1,030/333,113
"Top 10%"
Top management - top 3
| Lars Petersen 2 | Director |
Board - top 3
| Martin Edward Meeson 2 | Chairman of board |
| Lars Petersen 2 | Boardmember |
| Takatoshi Ishikawa 1 | Boardmember |
Legal owners - top 3
Rights certificate
Selskabet tegnes af et bestyrelsesmedlem alene. Bestyrelsen kan via fuldmagt bemyndige en person eller flere personer til at tegne på Selskabets vegne.
Company information based on CVR
| Name | Fujifilm Diosynth Biotechnologies Denmark Aps |
|---|---|
| CVR | 26060702 |
| Address | Biotek Allé 1, 3400 Hillerød |
| Industry | Manufacture of pharmaceutical preparations [212000] |
| Established | 01-06-2001 (22 yr) |
| Company type | Limited Corporation (APS) |
| Number of employees | 1181 (man years:1168) |
| Advertising protection | No |
| Auditor | Kpmg P/S since 01-08-2019 |
| Financial statement period | 01-04 to 31-03 |
| Company capital | 390,000 DKK 385,000 DKK (10-04-2008 - 06-05-2008) 380,000 DKK (15-01-2008 - 09-04-2008) 375,000 DKK (01-10-2007 - 14-01-2008) 370,000 DKK (07-08-2007 - 30-09-2007) 365,000 DKK (20-04-2007 - 06-08-2007) |
| Articles of assoc. last | 27-10-2021 |
Member of industries
- Manufacture of pharmaceutical preparationsNACE6 containing 216 comp.
- Manufacture of pharmaceutical preparationsNACE3 containing 216 comp.
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE2 containing 253 comp.
- ManufacturingNACE1 containing 26,642 comp.
Purpose
Selskabets formål er at drive produktions- og handelsvirksomhed og at besidde kapitalandele i andre virksomheder samt at drive anden virksomhed, der efter direktionens skøn er forbunden hermed.
Financial Statement
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Currency/unit | 000' DKK | 000' DKK | 000' DKK |
| Revenue | 3,068,983 +13% | 2,727,431 - | 2,039,469 - |
| Gross Profit | 583,823 +18% | 494,437 - | 65,121 - |
| Profit for the year | 213,460 +106% | 103,550 - | -176,316 - |
| Equity | 4,078,878 +6% | 3,865,418 - | 3,761,868 - |
| Total Assets | 8,455,622 +45% | 5,848,427 - | 5,508,130 - |
Mangement review
A significant improvement in the activities in the business areas resulting in higher than expected revenue and profit.
Revenue and Profit
The company delivered a total revenue of DKK 3,069.0 million in financial year 2021/22 compared to DKK 2,727.4 million in the previous period.
The growth in revenue was 12.5%, which exceeded expectations.
Profit before tax was DKK 271.9 million compared to DKK 132.8 million in the previous year. The improvement can be attributed to the increased manufacturing activities in the drug substance manufacturing area.
The revenue in 2020/21 was negatively impacted throughout the year by USD exchange rates. The revenue in 2021/22 has been less impacted.
Net Profit
FDBD reported net profit of DKK 213.5 million in 2021/22 compared to DKK 103.6 million in 2020/21.
Investments
FDBD invested a total of DKK 2,617.9 million in tangible fixed assets in 2021/22. This is a significant increase compared to 2020/21. The investments are covering the expansion of the facility in building for the future project as well as the operational capital investment to support the continuous manufacturing. The impact of COVID-19 on the expansion was managed and mitigated during the year with the use of on-site testing, tracking of positive cases as well as working from home where possible.
Total assets increased in 2021/22. At year-end the total assets were DKK 8,455.6 million compared to the DKK 5,848.4 million the year before.
Equity
At the end of the financial year the equity shows DKK 4,078.9 million. The equity ratio decreased from 66.1% in 2020/21 to 48.2% in 2021/22.
Non-financial matters
Employees
We strive to be an attractive workplace, who can attract and retain the right employees with the right knowledge. This is essential to our current and future success as a company.
At the end of 2021/22 the company had 969 full time employees, which was 88 employees more than the 881 employees the year before. This increase in employees is driven by increase in business and expansion activities on the site. All of the employees work from the company’s site in Hillerød.
Revenue and Profit
The company delivered a total revenue of DKK 3,069.0 million in financial year 2021/22 compared to DKK 2,727.4 million in the previous period.
The growth in revenue was 12.5%, which exceeded expectations.
Profit before tax was DKK 271.9 million compared to DKK 132.8 million in the previous year. The improvement can be attributed to the increased manufacturing activities in the drug substance manufacturing area.
The revenue in 2020/21 was negatively impacted throughout the year by USD exchange rates. The revenue in 2021/22 has been less impacted.
Net Profit
FDBD reported net profit of DKK 213.5 million in 2021/22 compared to DKK 103.6 million in 2020/21.
Investments
FDBD invested a total of DKK 2,617.9 million in tangible fixed assets in 2021/22. This is a significant increase compared to 2020/21. The investments are covering the expansion of the facility in building for the future project as well as the operational capital investment to support the continuous manufacturing. The impact of COVID-19 on the expansion was managed and mitigated during the year with the use of on-site testing, tracking of positive cases as well as working from home where possible.
Total assets increased in 2021/22. At year-end the total assets were DKK 8,455.6 million compared to the DKK 5,848.4 million the year before.
Equity
At the end of the financial year the equity shows DKK 4,078.9 million. The equity ratio decreased from 66.1% in 2020/21 to 48.2% in 2021/22.
Non-financial matters
Employees
We strive to be an attractive workplace, who can attract and retain the right employees with the right knowledge. This is essential to our current and future success as a company.
At the end of 2021/22 the company had 969 full time employees, which was 88 employees more than the 881 employees the year before. This increase in employees is driven by increase in business and expansion activities on the site. All of the employees work from the company’s site in Hillerød.
29-09-2022